Ligand Pharmaceuticals Incorporated Stock News

KALA gets Fast Track Designation from the FDA for lead candidate KPI-012 to treat persistent corneal epithelial defects.

The mean of analysts' price targets for Ligand (LGND) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts

Ligand's strategy of providing development capital to high-quality assets with capable teams is paying off, as evidenced by the recent positive developments and advancements in its product pipeline. L

New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KAL

The average of price targets set by Wall Street analysts indicates a potential upside of 49.1% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positiv

Ligand Pharmaceuticals (LGND) announces better-than-expected results in fourth-quarter 2022. Stock is up in the after-market hours in response to the news.

Ligand (LGND) delivered earnings and revenue surprises of 10.57% and 24.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ligand Pharmaceuticals, Inc. (NASDAQ:LGND ) Q4 2022 Earnings Conference Call February 22, 2023 4:00 PM ET Company Participants Simon Latimer - Head, IR Todd Davis - CEO Tavo Espinoza - CFO Matthew Kor

LGND vs. INCY: Which Stock Is the Better Value Option?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

LGND vs. GMAB: Which Stock Is the Better Value Option?

Ligand (LGND) reports mixed third-quarter 2022 numbers, beating sales estimates but missing out on earnings. Share price rises as management lifts financial guidance for the year.

Ligand Pharmaceuticals, Inc. (NASDAQ:LGND ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Simon Latimer - Head, IR John Higgins - CEO Matthew Korenberg - President

Ligand (LGND) delivered earnings and revenue surprises of -8.89% and 71.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO--(BUSINESS WIRE)--Ligand to Report Third Quarter Financial Results on November 7